List of Ferriprox drug patents
Ferriprox is owned by Chiesi.
Ferriprox contains Deferiprone.
Ferriprox has a total of 6 drug patents out of which 0 drug patents have expired.
Ferriprox was authorised for market use on 09 September, 2015.
Ferriprox is available in solution;oral dosage forms.
Ferriprox can be used as method of treating transfusional iron overload.
The generics of Ferriprox are possible to be released after 25 October, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(6 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Apr 30, 2024 |
Drugs and Companies using DEFERIPRONE ingredient
Market Authorisation Date: 09 September, 2015
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic